Matches 1 - 50 out of 176 1 2 3 4 >
Match Document Document Title
7074401 Methods, devices, and compositions for lysis of occlusive blood clots while sparing wound sealing clots  
It has now been discovered that certain mutant forms of pro-urokinase (“pro-UK”), such as so-called pro-UK mutant “M5” (Lys 300 →His), perform in the manner of pro-UK in lysing “bad”...
7045280 Assay method  
The present invention provides a method for the measurement of the activity of a plasminogen activator, such as urokinase plasminogen activator (uPA) or tissue plasminogen activator (tPA) in a...
7041479 Enhanced in vitro synthesis of active proteins containing disulfide bonds  
Compositions and methods are provided for the enhanced in vitro synthesis of polypeptides containing disulfide bonds. In order to improve the performance of in vitro protein synthesis reactions,...
7022673 Method for increasing the serum half-life of a biologically active molecule  
A method is provided for preparing a biologically active molecule having an increased serum half-life. The method involves conjugating a polymer such as polyethylene glycol to the biologically...
6964764 Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin  
Methods of thrombolysis that allow the use of a fibrinolytic composition comprising reversibly inactivated acidified plasmin and the localized delivery of the plasmin to a vascular thrombotic...
6902884 Method and tool for prognosticating HIV infection in a subject by measuring soluble urokinase plasminogen activator receptor, degradation products thereof, and urokinase plasminogen activator receptor  
Method of diagnosing and/or prognosticating HIV infection in a subject comprising the steps of: (a) performing in vitro a measurement of the level of a marker in the form of (i) urokinase...
6899877 Process for generating plasmin in the vitreous of the eye and inducing separation of the posterior hyaloid from the retina  
A process for inhibiting vascular proliferation separately introduces components into the eye to generate plasmin in the eye in amounts to induce complete posterior vitreous detachment where the...
6846656 Process for producing N-acetylneuraminic acid  
The present invention provides a process for economically producing N-acetylneuraminic acid without using expensive materials such as pyruvic acid and phosphoenolpyruvic acid. The process...
6680174 Assay for growth differentiation factor 9  
The present invention relates to a method of identifying an agent which alters (inhibits, enhances) activity of GDF-9. The method involves combining cells having a receptor for GDF-9 and a gene,...
6585972 Process for crosslinking of collagen in the vitreous of the eye and inducing separation of the posterior hyaloid from the retina  
A process for inhibiting vascular proliferation introduces a composition into the eye inducing posterior vitreous detachment. The composition includes a combination of plasminogen, a collagen...
6569636 Assay for modulators of metallo-enzyme activity  
An assay is disclosed for determining whether a test compound modulates the activity of an enzyme having a metallated active site. The assay method employs a comparison of the binding ability of...
6548276 Enhanced in vitro synthesis of active proteins containing disulfide bonds  
Compositions and methods are provided for the enhanced in vitro synthesis of polypeptides containing disulfide bonds. In order to improve the performance of in vitro protein synthesis reactions,...
6403556 Pharmaceutical preparation containing protein C and a thrombolytically active substance  
A pharmaceutical preparation contains protein C and a thrombolytically active substance that does not activate protein C. This preparation prevents reocclusion usually occurring in the course of...
6355243 Method of thrombolysis by local delivery of active plasmin  
The invention provides an improved method of thrombolytic therapy by the direct admiistration of active plasmin to a clot site via catheter. An active, stable preparation of plasmin is provided, as...
6239106 Family of protease inhibitors, and other biologic active substances  
The invention relates to novel protease-inhibitors which are obtainable from leeches. It also relates to uses thereof, for instance as a medicament, thus pharmaceutical preparations are provided,...
6190659 Bacterial plasmin binding protein and methods of use thereof  
The present invention describes a novel polypeptide, and methods of its use in effective thrombolytic therapy in the treatment of coronary and pulmonary thrombosis. Its use is also disclosed in...
6120765 Urokinase plasminogen activator fragments  
Purified uPA peptides having, mitogenic activity and containing as few as six amino acids of the EGF-like domain of uPA.
6113897 Antibodies and their use  
A monoclonal or polyclonal antibody directed against urokinase plasminogen activator receptor (u-PAR), or a subsequence, analogue or glycosylation variant thereof. Antibodies are disclosed which...
6022854 Platelet specific therapeutic compound and method of treating  
A therapeutic compound comprises a KGD-containing peptide, tandem repeats thereof, combinations thereof, or combinations thereof with an RGD-containing peptide or tandem repeats thereof, or peptide...
5976532 Method of antithrombotic therapy using anti-GPIIb/IIIa antibodies or fragments thereof, including c7E3  
Platelet-specific, chimeric immunoglobulin and immunoglobulin fragments are described. The chimeric molecules are made up of a nonhuman antigen binding region and a human constant region. Preferred...
5935789 Autonomously replicating sequences, GAPDH gene and promoter derived from Hansenula polymorpha, expression vectors containing same and method for the selection of transformants  
Autonomously replicating sequences(ARS), glyceraldehyde-3-phosphate dehydrogenase(GAPDH) gene and GAPDH promoter derived from Hansenula polymorpha DL-1(ATCC 26012); a vector for H. polymorpha which...
5866358 Production of human prourokinase  
A method is provided for producing non-glycosylated single chain prourokinase (proUK). The method comprises cultivating bacterial strains of E. coli which have been transformed with plasmids...
5811252 Modified proenzymes as substrates for proteolytic enzymes  
Detection or determination of a protease in a sample by incubating the sample with a substrate of the protease and observing proteolytic cleavage of said substrate. The substrate is a modified...
5770425 Human tissue plasminogen activator variants  
Disclosed are novel variants of tissue plasminogen activator (t-PA) that have surprising biological/pharmacokinetic properties compared with native t-PA. For example, certain of the variants hereof...
5759542 Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases  
A fusion drug including an isolated portion of the A-chain of a urokinase-type plasminogen activator linked to a drug, wherein the A-chain portion binds stably to an outer membrane of a platelet....
5750172 Transgenic non human mammal milk  
This invention relates to the production of recombinant proteins, such as coagulation factors VIII and IX, tissue plasminogen activator (TPA), urokinase, growth hormone, insulin, interferons,...
5731186 Method for the production of rDSPA α1  
rDSPA α1 is produced in commercial quantities and a purity adequate for clinical standards. The production methods utilize a series of chromatographic steps: cation exchange chromatography,...
5728564 U-PA mutants resistant to inhibition by their cognate inhibitors  
The present invention relates to serine protease mutants of the chymotrypsin superfamily that are resistant to inhibition by their cognate inhibitors, and genes that encode the same. The present...
5688503 Modification of plasminogen activators  
Phosphorylated plasminogen activator, such as phosphorylated pro-urokinase (pro-u-PA), which is substantially free from unphosphorylated plasminogen activator, may be obtained by phosphorylating...
5653979 Immunotargeting of plasminogen activators to the pulmonary endothelium  
A multimolecular complex made up of a plasminogen activator conjugated to anti-ACE Mab 9B9 capable of delivering the plasminogen activator to the pulmonary endothelium is provided. Methods of using...
5648253 Inhibitor-resistant urokinase  
Mutants of human urokinase are produced which have an altered amino acid sequence in the domain responsible for binding of plasminogen activator inhibitor(s). One example of an inhibitor resistant...
5637503 Plasmids, their construction and their use in the manufacture of a plasminogen activator  
Plasmids containing synthetic DNA sequences are described which are suitable for the expression of the intermediate protein of the recombinant scu-PA (i.e., the unglycosylated protein moiety of the...
5637299 Enhancement of thrombolytic therapy with deglycosylated forms of plasminogen  
This invention provides an improved method for enhancing the activity of thrombolytic agents, including t-PA, scu-PA, tcu-PA, streptokinase, acylated plasminogen-streptokinase activator complex...
5632986 Phospholipid-targeted thrombolytic agents  
Conjugates with an affinity for phospholipids are disclosed. The conjugates comprise a first compound having affinity for phospholipids, with a binding constant that is not greater than about 10 -7...
5626841 Use of intra-platelet urokinase-type plasminogen activators for long-term inhibition of thrombosis  
A method of adjunctive therapy to inhibit reocclusions in a patient, e.g., after thrombolytic therapy or angioplasty, by administering to the patient a bolus of an amount of purified pro-urokinase...
5589169 Method and therapeutic compositions for the prevention of fibrin deposition or adhesions  
A method and pharmaceutical composition for the prevention of fibrin deposition or adhesion formation by topical application of a composition to a site of potential fibrin deposition or adhesion...
5580559 Hybrid plasminogen activator  
Novel single-chain hybrid plasminogen activators having an amino acid sequence composed of at least two subsequences corresponding in amino acid identity and number to subsequences of human t-PA...
5571708 Thrombin-activatable plasminogen activator  
A new chimeric plasminogen activator with high fibrin affinity was designed to bind to a fibrin clot and initiate clot destruction in the presence of thrombin, but not plasmin. The chimeric...
5514572 Method to maintain the activity in polyethylene glycol-modified proteolytic enzymes  
A method for preparing protease-polyethylene glycol adducts is presented wherein the immobilized reversible inhibitor, benzamidine, prevents reaction of activated polyethylene glycol with the...
5510330 Combinations of thrombolytically active proteins and non-heparin anticoagulants, and uses thereof.  
The invention involves thromboembolically effective compositions and therapeutic methods. Thrombolytically active proteins are combined with anticoagulants, as long as the anticoagulant is not...
5491082 Plasminogen activator covalently bonded to a porous body of β-tricalcium phosphate  
A plasminogen activator such as urokinase or tissue plasminogen activator is covalently bonded to a porous body composed of calcium phosphate to form a plasminogen activator-porous body complex....
5472851 Method of determining a plasminogen activator and its inhibitor  
The present invention relates to the use of a substance which inhibits the plasma proteins α 2 -AP and/or α 2 -M in the field of the determination and assay of plasminogen activators and...
5472692 Pro-urokinase mutants  
The invention relates to thrombolytically active pro-urokinase (pro-UK) mutants comprising the amino acid sequence of native pro-UK, but including a mutation which causes the pro-UK mutants to...
5426044 Minactivin compositions and antibodies to minactivin  
A novel human protein, minactivin, can be produced by recombinant DNA technology, Biologically active native minactivin, peptides derived from minactivin, and their amino acid sequences can also be...
5409700 Pharmaceutical compositions comprising modified and unmodified plasminogen activators  
The present invention relates to pharmaceutical compositions comprising a combination of two different plasminogen activators which are used for the prophylaxis and therapie of thrombosis.
5389538 Mutant human prourokinase  
A mutant human prourokinase wherein a neutral amino acid in the epidermal growth factor (EGF) region of human prourokinase (human PUK) has been replaced with a basic amino acid, or an acidic amino...
5376547 Des-epidermal growth factor plasminogen activators  
Des-epidermal growth factor homologous--plasminogen activators with greatly diminished affinity for liver membranes.
5366886 Human tissue plasminogen activator variant  
Disclosed are novel variants of tissue plasminogen activator (t-PA) that have surprising biological/pharmacokinetic properties compared with native t-PA. For example, certain of the variants hereof...
5350578 Inhibition of arterial thrombotic occlusion or thromboembolism  
The method of preventing arterial thrombotic occlusion or thromboembolism by administering plasma-derived or recombinant produced protein C alone or in combination with a thrombolytic agent or...
5342775 Plasminogen activator  
A novel plasminogen activator which is identical in peptide sequence to naturally occurring human prourokinase except that the 155th amino acid counting from the N-terminal amino acid (serine)] is...
Matches 1 - 50 out of 176 1 2 3 4 >